BioAtla Investor Presentation Deck

Focused pipeline with broad applicability of differentiated CAB assets designed to deliver near-term value CAB-ADCs Bispe CAB- CAB- cific TCE O/I CAB CAB Program BA3011 Mecbotamab Vedotin BA3021 Ozuriftamab Vedotin BA3071 BA3182 Additional programs bicatla Target AXL ROR2 CTLA-4 EpCAM x CD3 Various Indications STS & Bone Sarcoma NSCLC Ovarian Cancer* NSCLC SCCHN Melanoma Ovarian Cancer* Multiple tumor types** Adenocarcinoma** Multiple tumor types** Multiple tumor types** IND Enabling Pre-Clinical Phase 1 Clinical IIT, investigator-initiated trial; IND, investigational new drug; NSCLC, Non-small Cell Lung Cancer; SCCHN, Squamous Cell Carcinoma of the Head and Neck; STS, Soft Tissue Sarcoma; FPI, First Patient In. Phase 2 Clinical Anticipated 2023 Milestones ✓ Initiated UPS Phase 2, part 2 potentially registrational study (1H) ● Submitted Exposure-Response analysis to medical meeting (1H) ✓ Request FDA feedback re: Phase 2, part 2 NSCLC potentially registrational study design (1H) Receive FDA feedback re: Phase 2, part 2 NSCLC (2H) Initiate Phase 2, part 2 NSCLC potentially registrational study (2H) Phase 2 IIT interim data ovarian (2H) ● Enrolling more frequent dosing regimens in NSCLC as part of Phase 2, part 1 (1H) ● ✓ FPI SCCHN Phase 2 (1H) Initiated NSCLC Phase 2 more frequent, dose intensive regimens (1H) Prioritize registration indications (2H) Phase 2 IIT interim data ovarian (2H) Phase 1 data (2H) Initiate Phase 2 (2H) ✓ Phase 1 IND clearance (1H) ✓ Initiate Phase 1 (1H) Additional INDS, 2023 / 2024 *Phase 2 investigator-initiated trial for Ovarian Cancer ** Indications based upon tumor target expression BioAtla| Overview 8

View entire presentation